Before that, the Swiss pharma owned part of the company and held marketing rights outside the US to Herceptin as well as other Genentech drugs. Typically, the volume of a subcutaneous injection is ...

Roche has had time to defend Herceptin against biosimilars, however. A patent-protected subcutaneous formulation of the drug was launched some years ago, and now represents 50% or more of the market.

A subcutaneous formulation of Roche’s Perjeta and Herceptin breast cancer drugs works as well as an original intravenous (IV) version, a study has shown. Roche’s Genentech unit is developing a ...

HER2 is short for human epidermal growth factor receptor 2. Researchers discovered HER2 breast cancer in the 1980s. Too many copies of the HER2 gene or its overexpression appeared to cause an ...

received an FDA complete response letter (CRL) on Jan. 3 for its TX-05 BLA, a biosimilar that references Roche AG’s Herceptin (trastuzumab). The CRL cites unnamed issues that need to be addressed by ...

They were pleading for “access - not excuses” when it came to Genentech’s promising new treatment for metastatic breast cancer: a drug called trastuzumab, also known as Herceptin®.